Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 6 , Pages 470-478, November 2009

The existence of cognitive plateaus in Alzheimer's disease

  • Andrea C. Bozoki

      Affiliations

    • Department of Neurology, Michigan State University, East Lansing, MI, USA
    • Corresponding Author InformationCorresponding author. Tel.: 517-884-2482; Fax: 517-432-9414.
  • ,
  • Hyonggin An

      Affiliations

    • Department of Biostatistics, College of Medicine, Korea University, Seoul, Korea
  • ,
  • Eva S. Bozoki

      Affiliations

    • Brookhaven National Laboratories, Upton, NY, USA (retired)
  • ,
  • Roderick J. Little

      Affiliations

    • Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

Abstract 

Background

The objective of this study was to evaluate the existence of cognitive plateaus in some individuals during the course of Alzheimer's disease (AD).

Methods

Data came from the historical patient group collected via the Consortium to Establish a Registry for Alzheimer's Disease (CERAD, Duke University, 1988–1996). Data reduction was performed by using principal components analysis to derive a single cognitive measure (F1), followed by application of a novel plateau-searching algorithm to individual patient data, looking for stable periods of 3 years or longer. To evaluate the time dependence of F1, we fitted a linear mixed model to the group and to individual data points.

Results

Twenty-two percent of AD subjects (54/243) and 98% of healthy control subjects (253/258) exhibited a plateau. Within the AD plateau group, the most common pattern was a single plateau (mean, 3.6 years; range, 3 to 7 years) that extended for the entire measurement period (28/54 subjects). Briefer plateau durations were seen at the beginning or end of the measurement period. Initial cognitive function (F1) was slightly higher in the plateau group, which was also slightly older and less well-educated. Men and women were equally represented.

Conclusions

In a patient sample predating the widespread use of cholinesterase inhibitors, we found that approximately one fifth of individuals with AD demonstrated periods of prolonged cognitive stability. This significant interindividual variability must be considered when providing prognostic information to families and when assessing individual patient responses to pharmacotherapy. We advise caution when assessing results of potentially disease-modifying agents at the individual patient level.

Keywords: Alzheimer's disease, Cognition, Dementia, Neuropsychology

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1552-5260(09)02030-5

doi:10.1016/j.jalz.2009.05.669

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 6 , Pages 470-478, November 2009